Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek March 22, 2004 Gene G. Marcial	Look Who May Be Courting Bioenvision Genzyme may be interested in Bioenvision as well. Why? In 2001, Bioenvision licensed to ILEX the right to co-develop and market in the U.S. and Canada its Clorfarabine, a drug for leukemia. Bioenvision still holds the rights outside North America. The company will soon file for Food & Drug Administration approval of Clorfarabine, which has a $1 billion market potential.
The Motley Fool December 30, 2004 Charly Travers	Genzyme Enters Cancer Arena The approval of a new drug is a long-term opportunity for the biotech giant.
BusinessWeek May 2, 2005 Gene G. Marcial	What Other Biotechs See In Bioenvision Bioenvision's childhood leukemia drug Clofarabine has received FDA approval and is expected to increase the profitability of the drug maker.
BusinessWeek February 9, 2004 Gene G. Marcial	Envisioning A Buyout For Bioenvision What's George Soros buying? In biotech, he has accumulated 27% of Bioenvision, a little-known biopharma. Other investors: OrbiMed Advisors, with 8%, and Deutsche Bank, with nearly 5%.
BusinessWeek June 4, 2007 Gene G. Marcial	What Big Investors See In Bioenvision Bioenvision has attracted big investors.
The Motley Fool September 28, 2007 Brian Lawler	Bioenvision Shareholder Battle Genzyme announces that it "cannot and will not" raise its $5.60-a-share bid for Bioenvision before shareholders go to vote on its proposed takeover. Investors, take note.
The Motley Fool December 10, 2008 Brian Orelli	A Painless Advisory Panel Meeting Genzyme might be getting a Christmas present from the Food and Drug Administration. An FDA advisory panel unanimously recommended approval for Genzyme's osteoarthritis pain drug Synvisc-One.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool June 29, 2010 Brian Orelli	The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting.
The Motley Fool August 31, 2009 Brian Orelli	Good Luck, Genzyme -- You'll Need It The drugmaker faces an FDA advisory-panel showdown regarding its leukemia drug Clolar.
The Motley Fool May 26, 2010 Brian Orelli	Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool March 2, 2004 David Nierengarten	Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines.
The Motley Fool February 4, 2009 Brian Orelli	Not If, but When, for Lilly At least Lilly now knows that it's just a matter of time until the anti-clotting agent wins FDA approval.
The Motley Fool November 18, 2008 Brian Orelli	Genzyme Grounded for Thanksgiving The biotech won't get a decision on Myozyme until February.
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
The Motley Fool April 15, 2011 Luke Timmerman	Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe?
The Motley Fool May 30, 2007 Brian Lawler	Genzyme Gobbles Up a Partner Another day, another biotech acquisition for drugmaker Genzyme. Investors, with more than $500 million in free cash flow last year alone, Genzyme has money to spare.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool October 10, 2007 Brian Lawler	Bioenvision Demands a Recount Bioenvision decided to hold the polls open one more day, in hopes that some stockholders who hadn't yet participated would vote for their proposed acquisition by Genzyme.
The Motley Fool October 29, 2007 Brian Lawler	Genzyme Gets It Together Genzyme may not engender as much investor excitement as Carl-Icahn-acquisition-hyped biopharmas. But its diverse pipeline, and the strong performance it delivers quarter after quarter, deserve some investor attention.
Chemistry World April 24, 2008 James Mitchell Crow	FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches.
The Motley Fool November 14, 2008 Brian Orelli	Gravy or Turkey From the FDA? Johnson & Johnson, Genzyme, and AstraZeneca should be made aware of their FDA fate over the next few weeks.
The Motley Fool January 9, 2008 Brian Lawler	Tracking Genzyme The biopharma updates investors on what to expect for 2008.
The Motley Fool October 27, 2010 Selena Maranjian	When Hostile Takeovers Get Ugly Conflict between companies and potential buyers can spill over to hurt shareholders.
The Motley Fool October 2, 2007 Billy Fisher	Closure for Bristol-Myers Bristol-Myers will pay $515 million to resolve cases from state and federal authorities alleging that the company promoted products for uses that hadn't been approved by the FDA.
The Motley Fool April 24, 2008 Brian Lawler	FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results.
The Motley Fool February 18, 2005 John Bluis	Genzyme's Acquisitions Pay Off With some of this biotech's major decisions coming to fruition, shareholders can have more confidence that management can deliver on its promises.
The Motley Fool April 20, 2006 John Bluis	Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management.
Pharmaceutical Executive July 3, 2007	Deals: Actavis Going Private? The board of the Icelandic generics maker holds out for a better offer.... Mylan Wins Merck Generics Unit... Genzyme to Acquire Bioenvision... etc.
The Motley Fool July 26, 2010 Brian Orelli	Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete?
The Motley Fool July 27, 2007 Brian Lawler	Jumpstarting Genzyme A great quarter for Genzyme. All three of its top products had double-digit percentage sales gains; operating margins are up too.
American Family Physician December 1, 2000 William M. Rados	Online Information for Health Care Professionals The home page of the U.S. Food and Drug Administration has undergone a major revision. The agency's Web site, which includes more than 100,000 documents, is now easier to search and covers the full scope of the FDA's activities...
The Motley Fool September 13, 2010 Brian Orelli	When All Else Fails, Sell! Genzyme has no other choice.
The Motley Fool January 5, 2010 Brian Orelli	A Deal Manufactured by Necessity Genzyme gets some help from a new friend.
The Motley Fool August 30, 2010 Brian Orelli	Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition?
The Motley Fool January 26, 2005 John Bluis	Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease.
The Motley Fool November 19, 2009 Brian Orelli	This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous.
The Motley Fool July 26, 2010 Ryan McBride	How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis